Average weight fell 5.9%, 8.7% and 7.9% with daily doses of 6, 12 and 36 mg, respectively, versus 0.6% with placebo over 72 weeks.Average weight fell 5.9%, 8.7% and 7.9% with daily doses of 6, 12 and 36 mg, respectively, versus 0.6% with placebo over 72 weeks.

Figure from The Lancet Diabetes & Endocrinology

Randomized trial · 238 peopleOrforglipron

Paper

The American Journal of MedicineOct 31

Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease and Type 2 Diabetes: A Narrative Review

Figure from The American Journal of Medicine

ReviewSGLT2 inhibitors

Paper

Biomedicine & PharmacotherapyOct 31

Urinary tract and genital infections with dapagliflozin and empagliflozin across type 2 diabetes, heart failure, and chronic kidney disease: An indication- and sex-stratified disproportionality analysis of eudravigilance reports

Figure from Biomedicine & Pharmacotherapy

Case-control study of 8,156 peopleEmpagliflozin

Paper

Preprints.orgOct 31

Beyond Glycaemic Control: Efficacy and Safety of Newer Antidiabetic Agents in Patients with Cardiorenal Disease—A Narrative Review

Preprint: reviewInterventions

Paper

Friday, October 30

Frontiers in PsychiatryOct 30

Structured exercise and exercise-based rehabilitation for anxiety, depression and psychological distress in lung cancer patients and survivors: an umbrella review of systematic reviews and meta-analyses

Accepted, not yet published: systematic reviewExercise

Paper

Frontiers in OncologyOct 30

Unlocking Microbiome Secrets: A Systematic Review of Microbiome-Derived Biomarkers for Early Colorectal Cancer Detection

Accepted, not yet published: systematic reviewColorectal cancer

Paper

Frontiers in NeurologyOct 30

Comparative Efficacy of Weight-Loss and Diuretic-Based Pharmacotherapies for Obstructive Sleep Apnea: A Systematic Review and Network Meta-Analysis

Accepted, not yet published: meta-analysis of randomized trialsDiuretics

Paper

Frontiers in MedicineOct 30

Evolution of colorectal cancer screening technologies and health economic evaluation: optimization strategies based on an economic gradient and dynamic risk stratification

ReviewColorectal cancer

Paper

Frontiers in EndocrinologyOct 30

Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study

Cross-sectional study of 1,355 peopleMetabolic dysfunction-associated steatotic liver disease

Paper

Frontiers in EndocrinologyOct 30

The HERMES Study: Prospective Assessment of Hepatic and Renal Stiffness Using Two-Dimensional Shear Wave Elastography Following Six Months of SGLT2 Inhibitor Therapy in Adults with Type 2 Diabetes

Accepted, not yet published: cohort study of 54 peopleSGLT2 inhibitors

Paper

Frontiers in EndocrinologyOct 30

Can Individual Gastrointestinal Microbiome Composition and Diversity Predict Individual Clinical Response to Anti-Diabetic Medication in Human Adults? A Systematic Review and Narrative Synthesis

Accepted, not yet published: systematic review of studies in peopleGut and microbiome

Paper

Frontiers in EndocrinologyOct 30

Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes: Insulin Resistance, Liver–Pancreas Crosstalk, and Integrated Therapeutic Strategies

Accepted, not yet published: reviewMetabolic dysfunction-associated steatohepatitis

Paper

Frontiers in Cell and Developmental BiologyOct 30

Esketamine tied to less decline after surgery at 60–80 with sleep loss

Among sleep-deprived patients, cognitive decline seven days after surgery occurred in 32.5% without esketamine and 17.7% with it.Among sleep-deprived patients, cognitive decline seven days after surgery occurred in 32.5% without esketamine and 17.7% with it.